LakeShore Biopharma Co., Ltd (LSB)
NASDAQ: LSB · Real-Time Price · USD
0.7202
-0.0098 (-1.34%)
Aug 4, 2025, 11:40 AM - Market open
HashiCorp Employees
LakeShore Biopharma had 758 employees as of March 31, 2024. The number of employees decreased by 15 or -1.94% compared to the previous year.
Employees
758
Change (1Y)
-15
Growth (1Y)
-1.94%
Revenue / Employee
$111,803
Profits / Employee
-$18,177
Market Cap
29.68M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 758 | -15 | -1.94% |
| Mar 31, 2023 | 773 | -92 | -10.64% |
| Mar 31, 2022 | 865 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LSB News
- 3 days ago - LakeShore Biopharma Announces Fiscal Year 2025 Financial Results - PRNewsWire
- 27 days ago - LakeShore Biopharma Announces US$15 Million Private Placement Financing - PRNewsWire
- 3 months ago - LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell) - PRNewsWire
- 8 months ago - LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance - PRNewsWire
- 8 months ago - LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China - GlobeNewsWire
- 9 months ago - LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire
- 10 months ago - LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine - PRNewsWire
- 10 months ago - LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance - PRNewsWire